Taking A New Direction
to Treat Autoimmunity
Zag Bio is harnessing the immune system in a whole new way by targeting the thymus to change treatment possibilities for millions of patients with autoimmune diseases.
The thymus is the only location where self-antigens are presented to induce T cell central tolerance.
In the thymus, developing immune cells are trained to recognize and tolerate self, preventing them from attacking the body’s own tissues. Disruption of thymic T cell development leads to the development of autoimmune diseases.
Zag Bio’s proprietary approach treats autoimmune disease by engaging the body’s natural process for inducing T cell central tolerance.
We create thymus-targeted therapies.
Our bifunctional antibodies deliver self-antigens to specialized antigen-presenting cells in the thymus.
Innovating with Our Platform
Immune cells learn tolerance.
As a result, the developing immune cells learn to recognize, tolerate, and protect the body’s own tissues.
Leveraging Science of the Thymus
Autoimmunity is addressed at the site of disease.
Once trained, mature regulatory T cells exit the thymus and home to specific diseased tissues, restoring local immune tolerance.
Advancing Our Pipeline
We are taking a bold new direction for treating autoimmune disease, motivated by a shared commitment to deliver new and better therapies for patients.
We are intentionally navigating in new territory, energized by the challenges and promise that lies ahead.
See What’s Zagging
